Transcription of C 型肝炎治療ガイドライン （第2版） - jsh.or.jp
1 C 2013 11 ** * * ** Corresponding author: 173-8605 2 11 1 Tel 03(3964)1211 Fax 03(3964)6627 Email 2012 5 1 2013 8 ALT U/l +Peg-IFN -2b+ 3 1 Peg-IFN (IFN)
2 2013 11 2 +Peg-IFN + 3 IFN B C 1-1 C 1 1-2 C 2 IFN 3 2-1 IFN 3 2-1-1 IFN 3 2-1-2 PEG IFN 4 2-1-3 IFN 5 2-1-4 IFN 5 2-1-5 5 2-1-6 Peg-IFN -2a Peg-IFN -2b 6 2-1-7 IFN
3 7 2-1-8 IFN 9 2-1-9 IFN 9 2-1-10 SVR 10 2-2 10 2-2-1 11 2-2-2 11 2-3 12 2-3-1 12 2-3-1-1 12 2-3-1-2 14 2-3-2 16 2-3-3 18 2-3-4 19 2-4 20
4 2-4-1 20 2-4-1-1 20 2-4-1-2 23 2-4-1-3 24 2-4-2 25 2-4-3 25 2-4-4 26 2-5 1 27 2-5-1 Peg-IFN+ 28 2-5-1-1 28 2-5-1-2 28 2-5-1-3 30 2-5-2 +Peg-IFN+ 31 2-5-3 +Peg-IFN+ 32 2-5-3-1
5 33 2-5-4 IFN + 34 2-5-5 35 2-5-5-1 35 2-5-5-2 35 2-6 1 37 2-6-1 1 37 2-6-2 2 37 2-6-3 2 38 2-7 38 2-7-1 1 38 2-7-2 1 42 2-7-2-1 42 2-7-2-2 42 2-7-3 1 45 2-7-4 2 45
6 2-7-5 2 45 2-8 45 2-8-1 IFN 45 2-8-1-1 Peg-IFN+ 46 2-8-1-2 IFN 47 2-8-1-3 IFN 48 2-8-2 IFN 48 2-8-3 49 2-9 ALT 50 50 3-1 UDCA 50 3-2 SNMC 51 3-3 51 51
7 53 69 71 72 HCV 73 1 C Hepatitis C virus; HCV 1989 Choo 1) A 90% HCV HCV 1 7000 150 200 HCV 30% 70% HCV HCV 2) interferon.
8 IFN 1986 Hoofnagle A B IFN 3) 1991 1992 C IFN PCR IFN HCV RNA 4) 5-8) C HCV pegylated interferon; Peg-IFN (sustained virological response; SVR) HCV 1 SVR 40 50% HCV 2011 11 1 1 +Peg-IFN+ 3 SVR 70% 9-13) 201 11 (TMC435)14-16) 1 +Peg-IFN + 3 SVR 90% 15) 2 MK7009 BI-201335)
9 Peg-IFN+ 3 IFN free /NS5A 17, 18) DAAs (direct anti-viral agents) 3 C 1-1 C 2 HCV
